
PRAX
Praxis Precision Medicines Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
50.335
Open
47.710
VWAP
47.68
Vol
455.35K
Mkt Cap
1.02B
Low
46.155
Amount
21.71M
EV/EBITDA(TTM)
--
Total Shares
17.11M
EV
704.50M
EV/OCF(TTM)
--
P/S(TTM)
125.26
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
69.35K
-77.04%
--
--
157.13K
-55.99%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Praxis Precision Medicines, Inc. (PRAX) for FY2025, with the revenue forecasts being adjusted by -19.41% over the past three months. During the same period, the stock price has changed by 38.19%.
Revenue Estimates for FY2025
Revise Downward

-19.41%
In Past 3 Month
Stock Price
Go Up

+38.19%
In Past 3 Month
9 Analyst Rating

133.29% Upside
Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 113.38 USD with a low forecast of 61.00 USD and a high forecast of 270.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy

133.29% Upside
Current: 48.600

Low
61.00
Averages
113.38
High
270.00

133.29% Upside
Current: 48.600

Low
61.00
Averages
113.38
High
270.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$105 -> $115
2025-08-05
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$105 -> $115
2025-08-05
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Praxis Precision to $115 from $105 and keeps a Buy rating on the shares. The firm says the RADIANT trial data showcased vormatrigine's "best-in-disease" efficacy in highly refractory focal onset seizure.
Oppenheimer
Oppenheimer
Outperform
maintain
$97 -> $115
2025-07-08
Reason
Oppenheimer
Oppenheimer
Price Target
$97 -> $115
2025-07-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Praxis Precision to $115 from $97 and keeps an Outperform rating on the shares. The firm sees an attractive setup for investors into Phase 2 RADIANT study of vormatrigine in epilepsy patients. Oppenheimer anticipates the readout within the next few weeks, and sees potential upside for the shares upon vormatrigine demonstrating a monthly seizure frequency reduction over 50% with favorable safety/tolerability data, considering the study design with 8-week open-label treatment, prior Phase 2 POC data supporting potential efficacy, read-through from relutrigine in DEE patients, and Phase 2 data from potential competitor drugs XEN1101 and cenobamate. The firm's scenario analysis forecasts +15% probability-adjusted upside. Oppenheimer anticipates RADIANT results to inform the design of pivotal Phase 3 POWER2 study while Phase 2/3 POWER1 continues enrolling with topline results expected in the second half of 2025.
Oppenheimer
Jay Olson
Outperform
initiated
$97
2025-06-02
Reason
Oppenheimer
Jay Olson
Price Target
$97
2025-06-02
initiated
Outperform
Reason
Oppenheimer analyst Jay Olson assumed coverage of Praxis Precision with an Outperform rating and $97 price target following quarterly results. Given the multiple upcoming readouts across its pipeline, the firm remains encouraged by management's execution. For the vomatrigine program, Oppenheimer looks forward to the RADIANT and POWER1 registrational Phase 2/3 topline results, still expected in mid-2025 and the second half of 2025, respectively.
Needham
Ami Fadia
Strong Buy
Reiterates
$85
2025-04-08
Reason
Needham
Ami Fadia
Price Target
$85
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Maintains
$120 → $105
2025-03-03
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$120 → $105
2025-03-03
Maintains
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Maintains
$150 → $85
2025-03-03
Reason
Needham
Ami Fadia
Price Target
$150 → $85
2025-03-03
Maintains
Strong Buy
Reason
Needham lowered the firm's price target on Praxis Precision to $85 from $150 and keeps a Buy rating on the shares. The firm is removing Ulixa sales from its model after the company disclosed last week that Independent Data Monitoring Committee recommended that its study be stopped for futility, due to the results being unlikely to meet the primary efficacy endpoint, the analyst tells investors in a research note. At this time, the firm is assuming that the probability of success for this program is "minimal" until there is more clarity on the final topline, Needham added.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Praxis Precision Medicines Inc (PRAX.O) is -3.56, compared to its 5-year average forward P/E of -4.80. For a more detailed relative valuation and DCF analysis to assess Praxis Precision Medicines Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.80
Current PE
-3.56
Overvalued PE
-0.13
Undervalued PE
-9.46
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.10
Current EV/EBITDA
-2.29
Overvalued EV/EBITDA
1.02
Undervalued EV/EBITDA
-7.22
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
293.77
Current PS
2677.36
Overvalued PS
786.19
Undervalued PS
-198.65
Financials
Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
+102.91%
-76.07M
Operating Profit
FY2025Q2
YoY :
+117.67%
-71.13M
Net Income after Tax
FY2025Q2
YoY :
+90.23%
-3.31
EPS - Diluted
FY2025Q2
YoY :
+100.65%
-54.73M
Free Cash Flow
FY2025Q2
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
-54.18%
-2.46K
FCF Margin - %
FY2025Q2
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
1.1M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 339.12% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
348.8K
Volume
1
6-9
Months
79.4K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
1.1M
Volume
Months
6-9
4
1.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
1.1M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PRAX News & Events
Events Timeline
2025-08-04 (ET)
2025-08-04
08:34:23
Praxis Precision reports Q2 EPS ($3.31), consensus ($3.36)

2025-08-04
08:08:41
Praxis Precision announces topline results from Phase 2 RADIANT study

2025-07-17 (ET)
2025-07-17
08:03:02
Praxis Precision receives FDA Breakthrough Therapy Designation for relutrigine

Sign Up For More Events
Sign Up For More Events
News
9.5
08-04NewsfilterPinnedPraxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript
9.0
08-04BenzingaPinnedPraxis' Epilepsy Treatment Shows Promise With Decreased Seizures
7.0
08-06PRnewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
Sign Up For More News
People Also Watch

OCSL
Oaktree Specialty Lending Corp
13.360
USD
+0.60%

SABR
Sabre Corp
3.000
USD
+0.67%

NYAX
Nayax Ltd
42.550
USD
+0.75%

WLFC
Willis Lease Finance Corp
149.370
USD
+0.22%

GRDN
Guardian Pharmacy Services Inc
20.940
USD
+0.87%

MRTN
Marten Transport Ltd
12.110
USD
+0.50%

FSLY
Fastly Inc
6.520
USD
+2.19%

JBGS
JBG SMITH Properties
20.120
USD
-1.52%

EOSE
Eos Energy Enterprises Inc
6.460
USD
-0.77%

ELME
Elme Communities
16.250
USD
-0.91%
FAQ

What is Praxis Precision Medicines Inc (PRAX) stock price today?
The current price of PRAX is 48.6 USD — it has increased 1.69 % in the last trading day.

What is Praxis Precision Medicines Inc (PRAX)'s business?

What is the price predicton of PRAX Stock?

What is Praxis Precision Medicines Inc (PRAX)'s revenue for the last quarter?

What is Praxis Precision Medicines Inc (PRAX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Praxis Precision Medicines Inc (PRAX)'s fundamentals?

How many employees does Praxis Precision Medicines Inc (PRAX). have?
